Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: Midterm follow-up

Journal of Vascular and Interventional Radiology

Volumn 25, Issue 2, 2014, Pages

  Dekervel, Jeroen ^a,b   Van Malenstein, Hannah ^a,b   Vandecaveye, Vincent ^a   Nevens, Frederik ^a,b   Van Pelt, Jos ^a,b   Heye, Sam ^a   Laleman, Wim ^a,b   Van Steenbergen, Werner ^a,b   Vaninbroukx, Johan ^a   Verslype, Chris ^a,b   Maleux, Geert ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; BILIRUBIN; CISPLATIN; DOXORUBICIN; MICROSPHERE; POLYMER; SORAFENIB;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALCOHOL LIVER DISEASE; ANTIBIOTIC THERAPY; ARTICLE; ASCITES; BACTEREMIA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CASE STUDY; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CHOLECYSTITIS; CHOLESTASIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PANCREATITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPONSE EVALUATION CRITERIA IN SOLID TUMOR; RETRANSPLANTATION; SEPTIC SHOCK; SYSTEMIC THERAPY; TREATMENT RESPONSE; VERY ELDERLY;

BARCELONA CLINIC LIVER CLASS; BCLC; HCC; HEPATOCELLULAR CARCINOMA; MODIFIED RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; MRECIST; OLT; ORTHOTOPIC LIVER TRANSPLANTATION; SAE; SAP; SERIOUS ADVERSE EVENT; SUPERABSORBENT POLYMER;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MAGNETIC RESONANCE IMAGING; MALE; MICROSPHERES; MIDDLE AGED; NEOPLASM STAGING; POLYMERS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84893651094     PISSN: 10510443     EISSN: 15357732     Source Type: Journal    
DOI: 10.1016/j.jvir.2013.10.017     Document Type: Article

References (26)

1. G. Maleux, H. van Malenstein, and V. Vandecaveye et al. Transcatheter chemoembolization of unresectable hepatocellular carcinoma: current knowledge and future directions Dig Dis 27 2009 157 163
2. J. Lammer, K. Malagari, and T. Vogl et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study Cardiovasc Intervent Radiol 33 2010 41 52
3. M.J. Song, H.J. Chun, and S. Song do et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma J Hepatol 57 2012 1244 1250
4. R. Dhanasekaran, D.A. Kooby, C.A. Staley, J.S. Kauh, V. Khanna, and H.S. Kim Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC) J Surg Oncol 101 2010 476 480
5. H. van Malenstein, G. Maleux, and V. Vandecaveye et al. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma Onkologie 34 2011 368 376
6. M. Grosso, C. Vignali, and P. Quaretti et al. Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study Cardiovasc Intervent Radiol 31 2008 1141 1149
7. J. Bruix, M. Sherman, and J.M. Llovet et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 2001 421 430
8. Arbuck SG, Ivy SP, Setser A, et al. The Revised Common Toxicity Criteria: Version 2.0. Available at: http://ctep.cancer.gov. Accessed October 15, 2009.
9. R. Lencioni, and J.M. Llovet Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 30 2010 52 60
10. R. Lencioni New data supporting modified RECIST (mRECIST) for hepatocellular carcinoma Clin Cancer Res 19 2013 1312 1314
11. G. Poggi, P. Quaretti, and C. Minoia et al. Transhepatic arterial chemoembolization with oxaliplatin-eluting microspheres (OEM-TACE) for unresectable hepatic tumors Anticancer Res 28 2008 3835 3842
12. A. Seki, S. Hori, K. Kobayashi, and S. Narumiya Transcatheter arterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for 135 hepatocellular carcinoma patients: single-center experience Cardiovasc Intervent Radiol 34 2011 557 565
13. D.K. Reyes, J.A. Vossen, and I.R. Kamel et al. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States Cancer J 15 2009 526 532
14. K. Malagari, M. Pomoni, and T.N. Spyridopoulos et al. Safety profile of sequential transcatheter chemoembolization with DC Bead: results of 237 hepatocellular carcinoma (HCC) patients Cardiovasc Intervent Radiol 34 2011 774 785
15. K. Kubota, N. Hisa, and T. Nishikawa et al. Evaluation of hepatocellular carcinoma after treatment with transcatheter arterial chemoembolization: comparison of Lipiodol-CT, power Doppler sonography, and dynamic MRI Abdom Imaging 26 2001 184 190
16. J.H. Shim, H.C. Lee, and S.O. Kim et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models Radiology 262 2012 708 718
17. E.S. Jung, J.H. Kim, and E.L. Yoon et al. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization J Hepatol 58 2013 1181 1187
18. K. Malagari, M. Pomoni, and A. Kelekis et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma Cardiovasc Intervent Radiol 33 2010 541 551
19. M. Cescon, A. Cucchetti, M. Ravaioli, and A.D. Pinna Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate J Hepatol 58 2013 609 618
20. A. Vitale, F. D'Amico, and A.C. Frigo et al. Response to therapy as a criterion for awarding priority to patients with hepatocellular carcinoma awaiting liver transplantation Ann Surg Oncol 17 2010 2290 2302
21. G. Otto, M. Schuchmann, and M. Hoppe-Lotichius et al. How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE? J Hepatol 59 2013 279 284
22. M. Skowasch, J. Schneider, and G. Otto et al. Midterm follow-up after DC-BEAD-TACE of hepatocellular carcinoma (HCC) Eur J Radiol 81 2012 3857 3861
23. M. Burrel, M. Reig, and A. Forner et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design J Hepatol 56 2012 1330 1335
24. E.A. Tsochatzis, T. Meyer, J. O'Beirne, and A.K. Burroughs Transarterial therapies for hepatocellular carcinoma (HCC): a long way towards standardization J Hepatol 58 2013 194
25. R. Gillmore, S. Stuart, and A. Kirkwood et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization J Hepatol 55 2011 1309 1316
26. H.J. Prajapati, J.R. Spivey, and S.I. Hanish et al. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE) Ann Oncol 24 2013 965 973